CTRI/2022/02/040551已完成3 期
A Prospective, Double Blind, Randomized, Parallel, Single-Center, Two-Arm, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of KSM-66 Ashwagandha® capsule (300 mg) on Menopause Symptoms
Ixoreal Biomed0 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Adult female subjects of ageâ??s >= 45 years and <=55 years.
- •2.Female patients with clinical diagnosis of menopaue.
- •3.Patients who can and willing to provide written Informed Consent.
- •4.Female patients with BMI 20-30 Kg/m2.
- •5.Female patients who are having more than 10 Hot Flashes events per week.
- •6.Female patients willing to follow the procedures as per the study protocol.
- •7.Female patients who agree to take investigational product till Day 56.
- •8.Female patients who have not undergone any hormone therapy or antidepressant during the past 3 months before enrolment.
- •9.Patients having capability of complete compliance and completion of follow-up .
- •10.Participant / participantâ??s legally acceptable representative understands and can comply with clinical trial protocol requirements.
排除标准
- •1.Female patients Ë? 45 years or Ë? 55 years of age.
- •2.Female patients who are severely anemic.
- •3.Female patients who had previous treatment with hormonal and bio-identical hormonal therapy
- •4.Female patients having a history of any bleeding disorders.
- •5.Female patients having a history or presence of any medical conditions which impacts the quality of life.
- •6.Female patients with hypersensitivity to study product or placebo.
- •7.Female patients currently using vitamin or mineral supplements, nutritional supplements and or medical foods estrogen, selective serotonin reuptake inhibitors within 30 days before the commencement of study or during the study.
- •8.Female patients using prescription medications and/or non-prescription medications for acute medical conditions, semi-acute medical conditions, and weight loss.
- •9.Female patients who are currently pregnant and breast-feeding.
- •10.Female patients with current diagnosis or medical history of smoking, alcoholism and drug dependence.
- •11.Female patients having a history of breast, endometrial, other gynaecological cancer at any time or any other cancer within last 5 years.
- •12.Female patients who are not willing to take investigational product.
- •13.Patients with uncontrolled, unstable comorbidities.
- •14.Patients taking part in any other studies, including macro/micro/any other forms of dietary supplements/multivitamins or disease-specific oral nutrition supplements.
- •15.Any other condition which the principal investigator thinks may jeopardize the safety of patients with uncontrolled, unstable comorbidities.
- •16.Patients who had participated in other clinical trials during previous 3 months.
研究者
相似试验
已完成
不适用
To Evaluate The Safety and Efficacy of KSM-66 Ashwagandha®capsule (300 mg) on Immune Function Enhancement and Quality of Life (QoL) in Healthy SubjectsCTRI/2022/02/040494Ixoreal Biomed60
进行中（未招募）
3 期
To evaluate the effect of KSM-66 Ashwagandha® capsule (300 mg) on Subclinical HypothyroidismCTRI/2022/02/040565Ixoreal Biomed
招募中
2 期
A clinical study to assess the effect of Rasayanam Gluco-Care in subjects with Type 2 Diabetes MellitusCTRI/2024/04/065722Rasayanam Enterprises
已完成
3 期
To evaluate the safety and efficacy of Ashwagandha Root Extract (150 mg) for Management of Mild Form of Attention Deficit Hyperactivity Disorder (ADHD) in Children and AdolescentsCTRI/2022/02/040555Ixoreal Biomed58
已完成
4 期
A study to compare a Fixed Dose Combination of Mometasone Furoate 0.1% + Fusidic Acid 2% Cream and Fixed Dose Combination of Betamethasone Valerate 0.1% + Neomycin Sulphate 0.5% Cream in Patients suffering from infected eczemaCTRI/2011/091/000062Glenmark Pharmaceuticals Ltd Glenmark House B D Sawant Marg Chakala Andheri East Mumbai192